RxDoctor Payments Data

Derrick Wong, MD

Hematology & Oncology · Mountain View, CANPI 1194941104

Payments from drug & device makers

$636in general payments, 2019–2025

Across 16 payments — averaging $39.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Athenex Pharmaceutical Division, LLC$175
  • AstraZeneca$125
  • Pfizer$98
  • Merck$96
  • AbbVie$26
  • American Orthodontics Corporation$25
  • plus $91 from 6 others

What the payments were for

  • Speaking & faculty fees$17532%
  • Food & beverage$19236%
  • Education$14827%
  • Entertainment$255%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$636 in reported general payments places this provider in the 20th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California

Medicare billing

Part B allowed, 2024
$3,980,432
Medicare patients
905
Services billed
161,982

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrukinsaZanubrutinib38$572,856
PomalystPomalidomide26$562,466
RevlimidLenalidomide28$514,199
TagrissoOsimertinib Mesylate31$503,168
Lenalidomide35$451,339
TasignaNilotinib Hcl18$381,436
ErleadaApalutamide24$340,440
EliquisApixaban164$223,716
BesremiRopeginterferon Alfa-2b-Njft12$219,645
SprycelDasatinib12$137,328
PromactaEltrombopag Olamine11$92,117
Abiraterone Acetate44$59,470
XareltoRivaroxaban29$41,124
Atovaquone11$4,504
Anastrozole116$2,529

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso$125$503,16831 claims
Johnson & JohnsonErleada, Xarelto$13$381,56553 claims
PfizerEliquis$98$223,716164 claims
Pharmaessentia USA CorporationBesremi$12$219,64512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 1,363 hematology & oncology providers in California.

Other hematology & oncology in Mountain View

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →